Clinuvel Pharmaceuticals (CLVLF) Stock Statistics & Valuation Metrics

Clinuvel Pharmaceuticals has a market cap or net worth of $336.61M. The enterprise value is ―.

Clinuvel Pharmaceuticals has 50,123,630 shares outstanding. The number of shares has decreased by -2.65% in one year.

Clinuvel Pharmaceuticals ’s return on equity (ROE) is 0.18 and return on invested capital (ROIC) is 16.36%.

The current PE Ratio of Clinuvel Pharmaceuticals is 21.88. Clinuvel Pharmaceuticals ’s PEG ratio is 1.74.

In the last 12 months, Clinuvel Pharmaceuticals had revenue of 88.18M and earned 35.64M in profits. Earnings per share was 0.72.

In the last 12 months, operating cash flow was 23.83M and capital expenditures -332.53K, giving a free cash flow of 23.49M billion.

Clinuvel Pharmaceuticals pays an annual dividend of $0.032, resulting in a dividend yield of 0.44%

Clinuvel Pharmaceuticals upcoming earnings date is Sep 2, 2025, TBA Not Confirmed.

Clinuvel Pharmaceuticals as a current ratio of 8.81, with Debt / Equity ratio of 0.33%

In the past 12 months, Clinuvel Pharmaceuticals has paid 15.04M in taxes.

Clinuvel Pharmaceuticals EV to EBITDA ratio is 11.50, with an EV/FCF ratio of 18.95.

Clinuvel Pharmaceuticals has $198.22M in cash and marketable securities with AU$715.38K in debt, giving a net cash position of -$197.51M billion.

Gross margin is 90.83%, with operating margin of 54.44%, and net profit margin of 40.41%.

The average price target for Clinuvel Pharmaceuticals is $25.48, which is 11.43% higher than the current price. The consensus rating is Moderate Buy